{"title":"Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely","authors":"H. Yanai, H. Adachi","doi":"10.2174/1876524601104010001","DOIUrl":null,"url":null,"abstract":"Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1). This protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion. Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events. Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.","PeriodicalId":22762,"journal":{"name":"The Open Diabetes Journal","volume":"26 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Diabetes Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876524601104010001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1). This protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion. Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events. Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.